Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to -$16.4 million.

  • Avalo Therapeutics' Cash from Operations fell 4197.1% to -$16.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.3 million, marking a year-over-year decrease of 4220.46%. This contributed to the annual value of -$49.1 million for FY2024, which is 6003.91% down from last year.
  • Avalo Therapeutics' Cash from Operations amounted to -$16.4 million in Q3 2025, which was down 4197.1% from -$11.3 million recorded in Q2 2025.
  • Over the past 5 years, Avalo Therapeutics' Cash from Operations peaked at $5.7 million during Q3 2022, and registered a low of -$19.2 million during Q2 2021.
  • Over the past 5 years, Avalo Therapeutics' median Cash from Operations value was -$11.5 million (recorded in 2024), while the average stood at -$11.3 million.
  • Per our database at Business Quant, Avalo Therapeutics' Cash from Operations skyrocketed by 13515.04% in 2022 and then plummeted by 44548.08% in 2024.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Cash from Operations stood at -$17.1 million in 2021, then skyrocketed by 76.96% to -$3.9 million in 2022, then increased by 29.8% to -$2.8 million in 2023, then crashed by 445.48% to -$15.1 million in 2024, then dropped by 8.46% to -$16.4 million in 2025.
  • Its Cash from Operations stands at -$16.4 million for Q3 2025, versus -$11.3 million for Q2 2025 and -$9.5 million for Q1 2025.